Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease
Author(s)
Yeoh, ZH; Wei, A;
Details
Publication Year 2023-04,Volume 64,Issue #4,Page 757-760
Journal Title
Leukemia & Lymphoma
Publication Type
Commentary
Publisher
Taylor & Francis
Keywords
Humans; *Blast Crisis/drug therapy; *Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Bridged Bicyclo Compounds, Heterocyclic/adverse effects; Sulfonamides/therapeutic use; Fusion Proteins, bcr-abl/genetics
Department(s)
Clinical Haematology
PubMed ID
37037568
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-07 07:16:24
Last Modified: 2023-08-07 07:17:40
An error has occurred. This application may no longer respond until reloaded. Reload 🗙